特瑞普利单抗联合TP化疗方案治疗老年晚期NSCLC伴TP53基因突变患者的效果  

Effects of Toripalimab combined with TP chemotherapy in treatment of elderly patients with advanced NSCLC with TP53 gene mutation

作　　者：杨迎春 YANG Yingchun(ICU of the First Affiliated Hospital of Nanyang Medical College,Nanyang 473000 Henan,China)

机构地区：[1]南阳医学高等专科学校第一附属医院呼吸与危重症医学科,河南南阳473000

出　　处：《中国民康医学》2025年第7期54-56,60,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察特瑞普利单抗联合TP化疗方案治疗老年晚期非小细胞肺癌(NSCLC)伴TP53基因突变患者的效果。方法:选取2021年11月至2023年11月该院收治的80例老年晚期NSCLC伴TP53基因突变患者进行前瞻性研究,按照随机数字表法将其分为对照组与观察组各40例。对照组采用TP化疗方案治疗,观察组在对照组基础上联合特瑞普利单抗治疗。比较两组临床疗效,治疗前后肿瘤标志物[癌抗原12-5(CA12-5)、癌胚抗原(CEA)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]、T细胞亚群指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平,以及不良反应发生率。结果:观察组客观缓解率为45.00%(18/40),高于对照组的22.50%(9/40),观察组疾病控制率为82.50%(33/40),高于对照组的62.50%(25/40),差异均有统计学意义(P<0.05);治疗后,两组CA12-5、CEA、CYFRA21-1水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组CD4^(+)、CD4^(+)/CD8^(+)水平均低于治疗前,但观察组高于对照组,两组CD8^(+)水平均高于治疗前,但观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:特瑞普利单抗联合TP化疗方案治疗老年晚期NSCLC伴TP53基因突变患者可提高客观缓解率和疾病控制率,改善T细胞亚群指标水平,以及降低肿瘤标志物水平,效果优于单纯TP化疗方案治疗。Objective:To observe effects of Toripalimab combined with TP chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer(NSCLC)with TP53 gene mutation.Methods:A prospective study was conducted on 80 elderly patients with advanced NSCLC and TP53 gene mutation admitted to the hospital from November 2021 to November 2023.According to the random number table method,they were divided into control group and observation group,40 cases in each group.The control group was treated with TP chemotherapy,while the observation group was treated with Toripalimab on the basis of that of the control group.The clinical efficacies,the levels of tumor markers[carbohydrate antigen 12-5(CA12-5),carcinoembryonic antigen(CEA),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)]and T cell subsets(CD4^(+),CD8^(+),CD4^(+)/CD8^(+))before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The objective remission rate of the observation group was 45.00%(18/40),which was higher than 22.50%(9/40)of the control group;the disease control rate of the observation group was 82.50%(33/40),which was higher than 62.50%(25/40)of the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of CA12-5,CEA and CYFRA21-1 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in the two groups were lower than those before the treatment,but those in the observation group were higher than those in the control group;the levels of CD8^(+)in the two groups were higher than those before the treatment,but that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).C

关 键 词：非小细胞肺癌 TP53基因突变 特瑞普利单抗 肿瘤标志物 T细胞亚群 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]